Stradling represented CombiMatrix Corporation with its $34.9 million sale to Invitae Corporation (NYSE:NVTA), one of the fastest growing genetic information companies. Read the press release.
CombiMatrix specializes in pre-implantation genetic diagnostics and screening, prenatal diagnosis, miscarriage analysis and pediatric developmental disorders, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies.
The deal team, led by Parker Schweich, included Kyle Leingang, Sonya Attal and Matthew Brodsky. Also assisting on the deal were Doug Hahn, Marc Schneider, Stephen Ram, Karla Kraft, Justin Owens, Kristin Larson, Rick Wagner, Joseph Haney and Arnold Mina.